Develops investigational cancer medicines, including PIKTOR, for patients with endometrial and breast cancer.
10-K for FY2025, filed Mar 30, 2026
No revenue reported yet.
10-K for FY2025, filed Mar 30, 2026
10-Q for Q3 FY2026, filed Nov 3, 2026
−$20.4MView ↗
8-K, filed Nov 9, 2026
Faeth Reports Positive Preliminary Phase 2 Topline Results from the PIK-201 Trial Evaluating PIKTOR in Combination with Paclitaxel in…View ↗
8-K, filed Jun 15, 2026
— Company changed name to Faeth Therapeutics, Inc. on June 15, 2026; common stock expected to begin trading under the ticker symbol “FTH”…View ↗
From immune checkpoint antibodies to PIKTOR
The older report centered on tumor-microenvironment antibodies aimed at immune signals. The latest report centers on PIKTOR, an oral combination that inhibits multiple nodes of a cancer pathway, for endometrial and breast cancer.
10-K for FY2022, filed Mar 29, 2023 10-K for FY2025, filed Mar 30, 2026We are an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through our…View ↗
We currently have three investigational product candidates in various stages of early development:View ↗
SNS-101 is our conditionally active monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T-cell…View ↗
We are a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical…View ↗
Following the Acquisition, our lead program is PIKTOR, an investigational multi-node inhibitor, or MNI, of the PI3K/AKT/mTOR pathway in…View ↗
PIKTOR, our lead clinical candidate, is an oral MNI of the PI3K/AKT/mTOR pathway. PIKTOR is comprised of two independently dosed inhibitors…View ↗
Competes with Celcuity, Kazia Therapeutics, Relay Therapeutics, Eli Lilly, Novartis, Synnovation Therapeutics, OnKure Therapeutics, and Laekna Therapeutics
10-K for FY2025, filed Mar 30, 2026Gedatolisib, an IV pan-PI3K/mTOR inhibitor from Celcuity, whose New Drug Application for HR+/HER2-, PIK3CA wild-type metastatic breast…View ↗
Loading...